Finally, this CPG includes the newest U.S. Food and Drug Administration (FDA) approved dyslipidemia treatments (e.g., bempedoic acid, icosapent ethyl), evaluates use of nutraceuticals and supplements for treatment of dyslipidemia, and has recommendations on practical exercise and the role of cardiac rehabilitation after a CVD event. b. Treatment Intensity Instead of Lipid Targets The Work Group carefully considered whether to use target levels for LDL-C but noted that the evidence relating patient-oriented outcomes to LDL-C levels consisted of trial comparisons between therapy intensities. Most often this consisted simply of active treatment versus placebo. Since no study prospectively evaluated LDL-C goals, the Work Group decided to focus on treatment intensity to match the evidence and simplify point of care decision making. The Work Group chose to use the common convention of moderate- and high-dose statins. Available statin doses are separated into moderate- and high-dose in Sidebar 3 of the algorithm. The Work Group is using the terms dose to represent what has also been called intensity. Both terms appear in the literature. G. Shared Decision Making This CPG encourages providers to practice shared decision making. Shared decision making was emphasized in Crossing the Quality Chasm, an Institute of Medicine (IOM) (now the NAM) report, in 2001.[18] Providers must be adept at presenting information to their patients regarding individual treatments, expected risks, expected outcomes, and levels and/or locations of care, especially as differences between risks and benefits become less clear. Providers are encouraged to use shared decision making strategies to individualize treatment goals and plans based on patient capabilities, needs, and preferences. H. Implementation This CPG and algorithm are designed to be adapted by individual healthcare providers with consideration of unique patient considerations and preferences, local needs, and resources. 